Scinai Immunotherapeutics Ltd. (TLV:BVXV)

Scinai Immunotherapeutics Statistics

Total Valuation

TLV:BVXV has a market cap or net worth of ILS 7.35 million. The enterprise value is 29.15 million.

Market Cap	7.35M
Enterprise Value	29.15M

Important Dates

The next estimated earnings date is Friday, March 27, 2026.

Earnings Date	Mar 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+157.30%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	3.06M

Valuation Ratios

The trailing PE ratio is 6.29.

PE Ratio	6.29
Forward PE	n/a
PS Ratio	1.90
PB Ratio	0.28
P/TBV Ratio	0.98
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	24.93
EV / Sales	8.15
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.52

Financial Position

The company has a current ratio of 0.71, with a Debt / Equity ratio of 0.30.

Current Ratio	0.71
Quick Ratio	0.53
Debt / Equity	0.30
Debt / EBITDA	n/a
Debt / FCF	-0.41
Interest Coverage	-6.67

Financial Efficiency

Return on equity (ROE) is 1,791.99% and return on invested capital (ROIC) is -44.45%.

Return on Equity (ROE)	1,791.99%
Return on Assets (ROA)	-39.55%
Return on Invested Capital (ROIC)	-44.45%
Return on Capital Employed (ROCE)	-86.89%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	124,664
Profits Per Employee	37,714
Employee Count	31
Asset Turnover	0.09
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	48.03
200-Day Moving Average	63.36
Relative Strength Index (RSI)	53.18
Average Volume (20 Days)	1,402,253

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.00

Income Statement

In the last 12 months, TLV:BVXV had revenue of ILS 3.86 million and earned 1.17 million in profits. Earnings per share was 0.89.

Revenue	3.86M
Gross Profit	-5.68M
Operating Income	-28.46M
Pretax Income	17.33M
Net Income	1.17M
EBITDA	-22.73M
EBIT	-28.46M
Earnings Per Share (EPS)	0.89

Balance Sheet

The company has 3.33 million in cash and 7.94 million in debt, with a net cash position of -4.61 million.

Cash & Cash Equivalents	3.33M
Total Debt	7.94M
Net Cash	-4.61M
Net Cash Per Share	n/a
Equity (Book Value)	26.48M
Book Value Per Share	4.96
Working Capital	-2.07M

Cash Flow

In the last 12 months, operating cash flow was -19.17 million and capital expenditures -53,909, giving a free cash flow of -19.22 million.

Operating Cash Flow	-19.17M
Capital Expenditures	-53,909
Depreciation & Amortization	5.26M
Net Borrowing	n/a
Free Cash Flow	-19.22M
FCF Per Share	n/a

Margins

Gross margin is -146.99%, with operating and profit margins of -736.36% and 448.39%.

Gross Margin	-146.99%
Operating Margin	-736.36%
Pretax Margin	448.39%
Profit Margin	448.39%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

TLV:BVXV does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-157.30%
Shareholder Yield	-157.30%
Earnings Yield	15.90%
FCF Yield	-261.46%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TLV:BVXV has an Altman Z-Score of -16.28 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-16.28
Piotroski F-Score	3